nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—Rifampicin—leprosy	0.135	0.548	CbGbCtD
Maraviroc—CYP3A4—Dapsone—leprosy	0.112	0.452	CbGbCtD
Maraviroc—CCR5—Binding and entry of HIV virion—CD4—leprosy	0.0628	0.34	CbGpPWpGaD
Maraviroc—Hodgkin's disease—Thalidomide—leprosy	0.0406	0.0714	CcSEcCtD
Maraviroc—Hodgkin's disease lymphocyte predominance type stage unspecified—Thalidomide—leprosy	0.0406	0.0714	CcSEcCtD
Maraviroc—Hodgkin's disease lymphocyte depletion type stage unspecified—Thalidomide—leprosy	0.0406	0.0714	CcSEcCtD
Maraviroc—Benign neoplasm of skin—Thalidomide—leprosy	0.0283	0.0497	CcSEcCtD
Maraviroc—CCR5—Early Phase of HIV Life Cycle—CD4—leprosy	0.023	0.125	CbGpPWpGaD
Maraviroc—Consciousness abnormal—Thalidomide—leprosy	0.0221	0.0388	CcSEcCtD
Maraviroc—Acquired immunodeficiency syndrome—Thalidomide—leprosy	0.0191	0.0335	CcSEcCtD
Maraviroc—Bronchopneumonia—Thalidomide—leprosy	0.0175	0.0308	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—RIPK2—leprosy	0.0165	0.0896	CbGpPWpGaD
Maraviroc—Septic shock—Thalidomide—leprosy	0.0127	0.0223	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—CD8A—leprosy	0.0125	0.0679	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—RIPK2—leprosy	0.012	0.0648	CbGpPWpGaD
Maraviroc—Polyneuropathy—Thalidomide—leprosy	0.0117	0.0207	CcSEcCtD
Maraviroc—Autoimmune disorder—Thalidomide—leprosy	0.0115	0.0202	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—HLA-DRB1—leprosy	0.0102	0.0553	CbGpPWpGaD
Maraviroc—Meningitis—Thalidomide—leprosy	0.00987	0.0174	CcSEcCtD
Maraviroc—Dementia—Thalidomide—leprosy	0.00933	0.0164	CcSEcCtD
Maraviroc—CCR5—TCR Signaling Pathway—CD8A—leprosy	0.00906	0.0491	CbGpPWpGaD
Maraviroc—Dysaesthesia—Thalidomide—leprosy	0.00885	0.0156	CcSEcCtD
Maraviroc—Proteinuria—Dapsone—leprosy	0.00851	0.015	CcSEcCtD
Maraviroc—Parkinsonism—Thalidomide—leprosy	0.00842	0.0148	CcSEcCtD
Maraviroc—Protein urine present—Dapsone—leprosy	0.00839	0.0148	CcSEcCtD
Maraviroc—Altered state of consciousness—Thalidomide—leprosy	0.00829	0.0146	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—IFNG—leprosy	0.00745	0.0404	CbGpPWpGaD
Maraviroc—CCR5—IL12-mediated signaling events—CD4—leprosy	0.0072	0.039	CbGpPWpGaD
Maraviroc—Venous thrombosis—Thalidomide—leprosy	0.00709	0.0125	CcSEcCtD
Maraviroc—CCR5—IL12-mediated signaling events—IL2—leprosy	0.00662	0.0359	CbGpPWpGaD
Maraviroc—CCR5—TCR Signaling Pathway—CD4—leprosy	0.0052	0.0282	CbGpPWpGaD
Maraviroc—Neuritis—Thalidomide—leprosy	0.00513	0.00901	CcSEcCtD
Maraviroc—Nasopharyngitis—Dapsone—leprosy	0.00485	0.00853	CcSEcCtD
Maraviroc—Myocardial ischaemia—Thalidomide—leprosy	0.00476	0.00837	CcSEcCtD
Maraviroc—Influenza—Dapsone—leprosy	0.00469	0.00825	CcSEcCtD
Maraviroc—Pancreatitis—Dapsone—leprosy	0.0046	0.00809	CcSEcCtD
Maraviroc—Acne—Thalidomide—leprosy	0.00455	0.008	CcSEcCtD
Maraviroc—Jaundice cholestatic—Thalidomide—leprosy	0.00436	0.00766	CcSEcCtD
Maraviroc—Proteinuria—Thalidomide—leprosy	0.00436	0.00766	CcSEcCtD
Maraviroc—Protein urine present—Thalidomide—leprosy	0.0043	0.00755	CcSEcCtD
Maraviroc—Hyperbilirubinaemia—Thalidomide—leprosy	0.00421	0.0074	CcSEcCtD
Maraviroc—Oliguria—Thalidomide—leprosy	0.00415	0.0073	CcSEcCtD
Maraviroc—Herpes simplex—Thalidomide—leprosy	0.00415	0.0073	CcSEcCtD
Maraviroc—Neuropathy peripheral—Dapsone—leprosy	0.0041	0.00721	CcSEcCtD
Maraviroc—Sinusitis—Dapsone—leprosy	0.00392	0.0069	CcSEcCtD
Maraviroc—CCR5—HIV Life Cycle—CD4—leprosy	0.00374	0.0203	CbGpPWpGaD
Maraviroc—Pharyngitis—Dapsone—leprosy	0.00373	0.00655	CcSEcCtD
Maraviroc—Colitis—Thalidomide—leprosy	0.00367	0.00646	CcSEcCtD
Maraviroc—Erythema—Dapsone—leprosy	0.00327	0.00575	CcSEcCtD
Maraviroc—Lymphadenopathy—Thalidomide—leprosy	0.00326	0.00573	CcSEcCtD
Maraviroc—Blood alkaline phosphatase increased—Thalidomide—leprosy	0.00319	0.00562	CcSEcCtD
Maraviroc—Diabetes mellitus—Thalidomide—leprosy	0.00319	0.00562	CcSEcCtD
Maraviroc—Deafness—Thalidomide—leprosy	0.00311	0.00546	CcSEcCtD
Maraviroc—Vascular purpura—Thalidomide—leprosy	0.00311	0.00546	CcSEcCtD
Maraviroc—Eczema—Thalidomide—leprosy	0.00309	0.00544	CcSEcCtD
Maraviroc—Renal failure acute—Thalidomide—leprosy	0.00301	0.00529	CcSEcCtD
Maraviroc—Amnesia—Thalidomide—leprosy	0.00296	0.0052	CcSEcCtD
Maraviroc—Dermatitis exfoliative—Thalidomide—leprosy	0.00294	0.00518	CcSEcCtD
Maraviroc—Purpura—Thalidomide—leprosy	0.00288	0.00507	CcSEcCtD
Maraviroc—Cough—Dapsone—leprosy	0.00285	0.00502	CcSEcCtD
Maraviroc—Cerebrovascular accident—Thalidomide—leprosy	0.00283	0.00499	CcSEcCtD
Maraviroc—CCR5—HIV Infection—CD4—leprosy	0.00258	0.014	CbGpPWpGaD
Maraviroc—Orthostatic hypotension—Thalidomide—leprosy	0.00254	0.00446	CcSEcCtD
Maraviroc—Breast disorder—Thalidomide—leprosy	0.00251	0.00441	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Thalidomide—leprosy	0.0025	0.0044	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Thalidomide—leprosy	0.0025	0.0044	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Thalidomide—leprosy	0.00245	0.00431	CcSEcCtD
Maraviroc—Abdominal distension—Thalidomide—leprosy	0.00242	0.00425	CcSEcCtD
Maraviroc—Insomnia—Dapsone—leprosy	0.00241	0.00424	CcSEcCtD
Maraviroc—Influenza—Thalidomide—leprosy	0.0024	0.00422	CcSEcCtD
Maraviroc—Eosinophilia—Thalidomide—leprosy	0.00238	0.00418	CcSEcCtD
Maraviroc—Bronchospasm—Thalidomide—leprosy	0.00236	0.00415	CcSEcCtD
Maraviroc—Pancreatitis—Thalidomide—leprosy	0.00235	0.00414	CcSEcCtD
Maraviroc—Angina pectoris—Thalidomide—leprosy	0.00234	0.00411	CcSEcCtD
Maraviroc—Bronchitis—Thalidomide—leprosy	0.00231	0.00406	CcSEcCtD
Maraviroc—Pancytopenia—Thalidomide—leprosy	0.00228	0.00401	CcSEcCtD
Maraviroc—Neutropenia—Thalidomide—leprosy	0.00225	0.00395	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Thalidomide—leprosy	0.00223	0.00392	CcSEcCtD
Maraviroc—Gastrointestinal pain—Dapsone—leprosy	0.00218	0.00384	CcSEcCtD
Maraviroc—Pneumonia—Thalidomide—leprosy	0.00215	0.00379	CcSEcCtD
Maraviroc—Infestation—Thalidomide—leprosy	0.00214	0.00376	CcSEcCtD
Maraviroc—Infestation NOS—Thalidomide—leprosy	0.00214	0.00376	CcSEcCtD
Maraviroc—Depression—Thalidomide—leprosy	0.00213	0.00375	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Thalidomide—leprosy	0.00212	0.00373	CcSEcCtD
Maraviroc—Acute coronary syndrome—Thalidomide—leprosy	0.00211	0.00371	CcSEcCtD
Maraviroc—Body temperature increased—Dapsone—leprosy	0.00211	0.00371	CcSEcCtD
Maraviroc—Abdominal pain—Dapsone—leprosy	0.00211	0.00371	CcSEcCtD
Maraviroc—Renal failure—Thalidomide—leprosy	0.0021	0.0037	CcSEcCtD
Maraviroc—Neuropathy peripheral—Thalidomide—leprosy	0.0021	0.00369	CcSEcCtD
Maraviroc—Myocardial infarction—Thalidomide—leprosy	0.0021	0.00369	CcSEcCtD
Maraviroc—Stomatitis—Thalidomide—leprosy	0.00209	0.00367	CcSEcCtD
Maraviroc—Conjunctivitis—Thalidomide—leprosy	0.00208	0.00366	CcSEcCtD
Maraviroc—Sinusitis—Thalidomide—leprosy	0.00201	0.00353	CcSEcCtD
Maraviroc—Agranulocytosis—Thalidomide—leprosy	0.002	0.00351	CcSEcCtD
Maraviroc—CCR5—Disease—SLC11A1—leprosy	0.00199	0.0108	CbGpPWpGaD
Maraviroc—Rhinitis—Thalidomide—leprosy	0.00193	0.00339	CcSEcCtD
Maraviroc—Pharyngitis—Thalidomide—leprosy	0.00191	0.00335	CcSEcCtD
Maraviroc—Urinary tract disorder—Thalidomide—leprosy	0.0019	0.00334	CcSEcCtD
Maraviroc—Urethral disorder—Thalidomide—leprosy	0.00188	0.00331	CcSEcCtD
Maraviroc—Erythema multiforme—Thalidomide—leprosy	0.00182	0.0032	CcSEcCtD
Maraviroc—Eye disorder—Thalidomide—leprosy	0.0018	0.00316	CcSEcCtD
Maraviroc—Cardiac disorder—Thalidomide—leprosy	0.00178	0.00314	CcSEcCtD
Maraviroc—Angiopathy—Thalidomide—leprosy	0.00174	0.00307	CcSEcCtD
Maraviroc—Mediastinal disorder—Thalidomide—leprosy	0.00173	0.00305	CcSEcCtD
Maraviroc—Alopecia—Thalidomide—leprosy	0.0017	0.00299	CcSEcCtD
Maraviroc—Vomiting—Dapsone—leprosy	0.0017	0.00298	CcSEcCtD
Maraviroc—Mental disorder—Thalidomide—leprosy	0.00168	0.00296	CcSEcCtD
Maraviroc—Malnutrition—Thalidomide—leprosy	0.00167	0.00294	CcSEcCtD
Maraviroc—Headache—Dapsone—leprosy	0.00167	0.00294	CcSEcCtD
Maraviroc—Flatulence—Thalidomide—leprosy	0.00165	0.0029	CcSEcCtD
Maraviroc—Nausea—Dapsone—leprosy	0.00158	0.00279	CcSEcCtD
Maraviroc—Tremor—Thalidomide—leprosy	0.00157	0.00276	CcSEcCtD
Maraviroc—Anaemia—Thalidomide—leprosy	0.00155	0.00272	CcSEcCtD
Maraviroc—Syncope—Thalidomide—leprosy	0.0015	0.00264	CcSEcCtD
Maraviroc—Leukopenia—Thalidomide—leprosy	0.0015	0.00263	CcSEcCtD
Maraviroc—Loss of consciousness—Thalidomide—leprosy	0.00147	0.00259	CcSEcCtD
Maraviroc—Cough—Thalidomide—leprosy	0.00146	0.00257	CcSEcCtD
Maraviroc—Convulsion—Thalidomide—leprosy	0.00145	0.00255	CcSEcCtD
Maraviroc—Myalgia—Thalidomide—leprosy	0.00142	0.0025	CcSEcCtD
Maraviroc—Anxiety—Thalidomide—leprosy	0.00142	0.0025	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.00141	0.00249	CcSEcCtD
Maraviroc—Discomfort—Thalidomide—leprosy	0.00141	0.00247	CcSEcCtD
Maraviroc—Oedema—Thalidomide—leprosy	0.00137	0.0024	CcSEcCtD
Maraviroc—Infection—Thalidomide—leprosy	0.00136	0.00239	CcSEcCtD
Maraviroc—Shock—Thalidomide—leprosy	0.00134	0.00236	CcSEcCtD
Maraviroc—Nervous system disorder—Thalidomide—leprosy	0.00134	0.00235	CcSEcCtD
Maraviroc—Skin disorder—Thalidomide—leprosy	0.00133	0.00233	CcSEcCtD
Maraviroc—Anorexia—Thalidomide—leprosy	0.0013	0.00229	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Thalidomide—leprosy	0.00124	0.00219	CcSEcCtD
Maraviroc—Insomnia—Thalidomide—leprosy	0.00123	0.00217	CcSEcCtD
Maraviroc—Paraesthesia—Thalidomide—leprosy	0.00123	0.00216	CcSEcCtD
Maraviroc—Decreased appetite—Thalidomide—leprosy	0.00119	0.00209	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Thalidomide—leprosy	0.00118	0.00207	CcSEcCtD
Maraviroc—Fatigue—Thalidomide—leprosy	0.00118	0.00207	CcSEcCtD
Maraviroc—Pain—Thalidomide—leprosy	0.00117	0.00205	CcSEcCtD
Maraviroc—Constipation—Thalidomide—leprosy	0.00117	0.00205	CcSEcCtD
Maraviroc—Gastrointestinal pain—Thalidomide—leprosy	0.00112	0.00196	CcSEcCtD
Maraviroc—Body temperature increased—Thalidomide—leprosy	0.00108	0.0019	CcSEcCtD
Maraviroc—Abdominal pain—Thalidomide—leprosy	0.00108	0.0019	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—RIPK2—leprosy	0.00102	0.00552	CbGpPWpGaD
Maraviroc—Hypersensitivity—Thalidomide—leprosy	0.00101	0.00177	CcSEcCtD
Maraviroc—Asthenia—Thalidomide—leprosy	0.00098	0.00172	CcSEcCtD
Maraviroc—Pruritus—Thalidomide—leprosy	0.000966	0.0017	CcSEcCtD
Maraviroc—Diarrhoea—Thalidomide—leprosy	0.000934	0.00164	CcSEcCtD
Maraviroc—Dizziness—Thalidomide—leprosy	0.000903	0.00159	CcSEcCtD
Maraviroc—Vomiting—Thalidomide—leprosy	0.000868	0.00153	CcSEcCtD
Maraviroc—Rash—Thalidomide—leprosy	0.000861	0.00151	CcSEcCtD
Maraviroc—Dermatitis—Thalidomide—leprosy	0.00086	0.00151	CcSEcCtD
Maraviroc—Headache—Thalidomide—leprosy	0.000855	0.0015	CcSEcCtD
Maraviroc—Nausea—Thalidomide—leprosy	0.000811	0.00143	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—IL2—leprosy	0.00076	0.00412	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL2—leprosy	0.00069	0.00374	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD4—leprosy	0.000633	0.00343	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL2—leprosy	0.000408	0.00221	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SDHD—leprosy	0.000166	0.000897	CbGpPWpGaD
